Cancerous disease modifying antibodies

Details Cancerous disease modifying antibodies Cancerous disease modifying antibodies

2007-02-22

2008-11-25

Rawlings, Stephen L (Department: 1643)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Animal cell, per se, expressing immunoglobulin, antibody, or...

C530S387100, C530S387300, C530S388800, C530S391300, C530S391700

Reexamination Certificate

active

07456016

ABSTRACT:
The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

REFERENCES:
patent: 4861581 (1989-08-01), Epstein et al.
patent: 5171665 (1992-12-01), Hellstrom et al.
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5693763 (1997-12-01), Codington et al.
patent: 5750102 (1998-05-01), Eisenbach et al.
patent: 5780033 (1998-07-01), Torchilin et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5849876 (1998-12-01), Linsley et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5869268 (1999-02-01), Kudo et al.
Gu et al., “Anti-Prostate Stem Cell Antigen Monoclonal Antibody 1G8 Induces Cell Death In vitro and Inhibits Tumor Growth In vivo via a Fc-Independent Mechanism”, Cancer Research (2005), vol. 65, pp. 9495-9500.
Kohler et al., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity”, Nature (Aug. 1975), vol. 256, pp. 495-497.
Sayegh et al., “97th American Association for Cancer Research”, Annual Meeting Apr. 1-5, 2006, Washington, D.C., Abstract 637.
Smith-Jones, “Radioimmunotherapy of Prostate Cancer”, The Quarterly Journal of Nuclear Medicine and Molecular Imaging (2004), vol. 48, pp. 297-304.
Vallabhajosula et al., “Radioimmunotherapy of Prostate Cancer Using 90Y- and 177Lu-Labeled J591 Monoconal Antibodies: Effect of Multiple Treatments on Myelotoxicity”, Clinical Cancer Research (2005), vol. 11, pp. 7195s-7200s.

Affiliated with

Also associated with

Rating

Cancerous disease modifying antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancerous disease modifying antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancerous disease modifying antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4043690